Skip to main content

Emergent BioSolutions Inc. Signs $480M Manufacturing Deal

Emergent BioSolutions Inc. has signed a $480M manufacturing deal with Johnson & Johnson to manufacture its COVID-19 vaccine candidate. The new five-year agreement follows a $135M deal dating back to April from Johnson & Johnson that supports large-scale manufacturing of J&J’s lead COVID-19 vaccine candidate at Emergent’s Baltimore City-based manufacturing facility. “We have the expertise and capabilities to meet the long-term needs of our customers and provide ongoing commercial manufacturing to benefit patients,” said Syed Husain, CMDO business unit head at Emergent.

Read More

Michele Whelley - President & CEO

"We want you to be informed about Greater Baltimore. Don't be shy; please ask."

Michele Whelley
President & CEO

We are here to help you!

If you've landed on this site, then you have questions about us, and we want to help. We know that your time is crucial, and getting access to us should not be a complicated thing. Drop us a note via one of the options below and we will get back to you within 24 hours.

(410) 864-9927